Rifaximin
Brand name: Xifaxan
Rank #57 of 500 drugs by total cost
$310.0M
Total Cost
111,328
Total Claims
$310.0M
Total Cost
4,328
Prescribers
$2,785
Cost per Claim
9,522
Beneficiaries
114,153
30-Day Fills
$72K
Avg Cost/Provider
26
Avg Claims/Provider
About Rifaximin
Rifaximin (sold as Xifaxan) was prescribed 111,328 times by 4,328 Medicare Part D providers in 2023, costing the program $310.0M. At $2,785 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 54 | Icosapent Ethyl (Vascepa) | $334.9M | 692,252 |
| 55 | Cariprazine Hcl (Vraylar) | $329.1M | 226,854 |
| 56 | Albuterol Sulfate (Albuterol Sulfate Hfa) | $312.2M | 7,904,120 |
| 57 | Rifaximin (Xifaxan) | $310.0M | 111,328 |
| 58 | Sitagliptin Phos/Metformin Hcl (Janumet) | $302.2M | 329,315 |
| 59 | Tofacitinib Citrate (Xeljanz Xr) | $294.4M | 49,478 |
| 60 | Umeclidinium Brm/Vilanterol Tr (Anoro Ellipta) | $294.3M | 480,651 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology